When tested in vivo, the TRAIL expressing ADV inhibited orthotopic tumor growth, with increased efficacy at a higher dose (4 × 108) and significantly prolonged survival in a metastatic tumor model, while also reducing metastases compared to control animals. The gene discussed is TNFSF10; the disease is neoplasm.